Placental Aromatase Deficiency: Difference between revisions
| Line 28: | Line 28: | ||
* Placental aromatase deficiency is a rare entity. | * Placental aromatase deficiency is a rare entity. | ||
As a result of defective synthesis of estrogen AD may result in : | |||
* Delayed Puberty | |||
* Insulin resistance | |||
* Polycystic ovarian disorder | |||
* Bone disorders | |||
* In patients with Aromatase deficiency lifetime hormone replacement therapy is mandatory. We can see osteoporosis as an outcome in male patients with late diagnosis, and these skeletal defects tend to remain even after hormonal treatment and sometimes require surgical correction. Moreover, the effects on glucose and lipid metabolism like adiposity and reproductive defects such as infertility are also not corrected by estradiol treatment. | * In patients with Aromatase deficiency lifetime hormone replacement therapy is mandatory. We can see osteoporosis as an outcome in male patients with late diagnosis, and these skeletal defects tend to remain even after hormonal treatment and sometimes require surgical correction. Moreover, the effects on glucose and lipid metabolism like adiposity and reproductive defects such as infertility are also not corrected by estradiol treatment. | ||
== Reference == | == Reference == | ||
Revision as of 16:18, 15 June 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Aromatase deficiency is an autosomal recessive disorder in which there is a decrease or absence in the level of aromatase in the body which leads to impairment in the conversion of androgens to estrogen. This is due to a genetic mutation in the CYP19A1, a subtype of [P450]. Patient affected by this disease typically presents with maternal virilization, amenorrhea in puberty in females. Males are rarely affected.
Historical Perspective
The evidence of the disease goes back to year 1991, when the first case of aromatase deficiency occurred [1]. Most of the cases were that of women during the third trimester of pregnancy presenting with maternal virilization resulting in hirsutism and acne.
Pathophysiology
CYP19A1 gene is responsible for the production of enzyme aromatase, which converts androgens to different forms of estrogen . Estrogen is involved in sexual development in females prior to birth and the levels peak during pregnancy. Mutation in CYP19A1 gene leads to deficiency or absence of activity of aromatase [2]. As a result, there is decrease in production of estrogen due to lack of conversion of androgens to estrogen and increase in testosterone and androstenedione levels. In pregnant women , excess androgens cross the placenta and enter into the maternal circulation leading to virilization. Female fetuses who are affected have ambiguous genitalia while males develop osteoporosis.
Causes
CYP19A1 gene mutation primarily causes Placental Aromatase Deficiency and the placenta is not capable of converting androgenic precursors of estrogen to estradiol. Mutations on exons 3,5 and 9 have been reported. Studies suggest that it is more prevalent in consanguinous marriages and both are heterozygous carriers of the mutation.
Differential Diagnosis
Congenital adrenal hyperplasia can be considered as a differential in female patients. While, in male patients;
- 5 alpha reductase deficiency
Key differentiating features: It is present exclusively in males (46,XY) and the levels of testosterone and estrogen are normal.
- Estrogen resistance syndrome
- 46,XY disorder of sex development due to isolated 17, 20 lyase deficiency
- Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency
- Congenital hypogonadotropic hypogonadism
can be considered as the differentials.
Natural History , Complications and Prognosis
- Placental aromatase deficiency is a rare entity.
As a result of defective synthesis of estrogen AD may result in :
- Delayed Puberty
- Insulin resistance
- Polycystic ovarian disorder
- Bone disorders
- In patients with Aromatase deficiency lifetime hormone replacement therapy is mandatory. We can see osteoporosis as an outcome in male patients with late diagnosis, and these skeletal defects tend to remain even after hormonal treatment and sometimes require surgical correction. Moreover, the effects on glucose and lipid metabolism like adiposity and reproductive defects such as infertility are also not corrected by estradiol treatment.
Reference
- ↑ Shouzu M, Akasofu K, Harada T, Kubota Y (March 1991). "A new cause of female pseudohermaphroditism: placental aromatase deficiency". J. Clin. Endocrinol. Metab. 72 (3): 560–566. doi:10.1210/jcem-72-3-560. PMID 1825497.
- ↑ Aromatase Deficiency 18 August, 2020. Retrieved 13 June 2021